Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

CAPS Rating: 2 out of 5

A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.

Results 1 - 11 of 11

Recs

3
Member Avatar zzlangerhans (99.81) Submitted: 2/18/2015 7:18:12 PM : Underperform Start Price: $0.93 CYCC Score: -61.00

In the last few months, lots of weak biopharmas took huge hits on negative catalysts and their share prices seemed to gravitate towards the 50 cent level with market caps at about half of cash on hand. I owned substantial chunks of almost all of them except for Cyclacel, probably because I didn't have time to keep up with the stock. We added to our destroyed positions in Regado, Sophiris, and KaloBios with mixed results so far. I wasn't much impressed with Cyclacel's prospects for recovery, given that the company was planning to continue their failed trial to completion on the remote chance that it might show a survival benefit on the tail end of the Kaplan-Meier curve. The company had nothing left in the pipeline except further early stage trials of sapacitabine and seliciclib, compounds that had failed repeatedly in the seven years I've followed Cyclacel. Nevertheless, I couldn't argue with Portefeuille's request to take a smallish 10000 share position at 0.6. Naturally, that was the one that took off, maxing out at 0.93 today. We completely liquidated our position for profits of about $2500.

I forgot to put in a green thumb on Cyclacel to correspond with our real position, but I won't forget to call a top with this red thumb. It's a good sign that CAPS miraculously started the pick at the correct share price and not the one half an hour earlier or half an hour later than when I made the call. Of course, I don't have any inside knowledge or technical skills that tell me that Cyclacel won't keep rising to 2 or whatever. On the other hand, tons of small cap zombie biopharmas that I know are crap such as Mela and Cytori went up today and I doubt all of them are going to have sustained runs. If they do, I'll be instituting a lot of new short positions. In the meantime, what does all this churn in microcaps mean for the sector? Possibly nothing, or possibly a sign of an overbought sector in the final spasms of a buying orgy before a bubble pops.

Recs

0
Member Avatar TerryFool (75.05) Submitted: 3/25/2014 5:50:51 AM : Outperform Start Price: $3.59 CYCC Score: -71.71

BUY@ 3.6 TP 10

Recs

0
Member Avatar TerryHoodSr (76.08) Submitted: 3/24/2014 6:50:19 PM : Outperform Start Price: $3.69 CYCC Score: -72.83

SPEC BUY@ 3.7 TP 10

Recs

0
Member Avatar UnstableEnabled (< 20) Submitted: 12/21/2013 3:30:17 AM : Outperform Start Price: $3.85 CYCC Score: -76.53

A boatload of good news will come Cyclacel's way in Q1 2014. (SEAMLESS) will continue successfully passing it's mid-point futility review at which time a partnership with big-pharma to fund an MDS Phase 3 trial will likely come to fruition.

It's entirely possible that other p.p.s. accelerators like accelerated approval and a SPA agreement with the FDA involving sapacitabine in MDS will advance the stock as well.

Sorely depressed, any good new will cause the stock to surge upward.

Recs

0
Member Avatar toegar2000 (57.47) Submitted: 3/2/2013 10:25:20 AM : Outperform Start Price: $5.50 CYCC Score: -111.54

Looks good IMO

Recs

0
Member Avatar stainsolution (64.37) Submitted: 4/9/2012 9:52:19 AM : Outperform Start Price: $4.55 CYCC Score: -119.74

Small Cancer/Bio

Recs

0
Member Avatar RBuskey106 (56.95) Submitted: 3/21/2012 8:23:14 PM : Outperform Start Price: $4.40 CYCC Score: -115.73

Small cancer bio

Recs

0
Member Avatar nwarrior (< 20) Submitted: 7/27/2011 2:55:42 AM : Outperform Start Price: $8.26 CYCC Score: -140.72

This stock is poised to rise, already near it's 52 Week low. With a high insider net holding volume and low debt, this is an investment with great potential.

Recs

0
Member Avatar rwaddoups (< 20) Submitted: 1/3/2011 1:22:52 PM : Outperform Start Price: $10.50 CYCC Score: -151.09

yes

Recs

0
Member Avatar verbatum (< 20) Submitted: 10/5/2010 8:03:18 PM : Outperform Start Price: $11.34 CYCC Score: -168.34

Great Pipeline,Great PHASE II, Entering PHASE III, Shelf registered, Orphan Designation

Recs

0
Member Avatar imrhh (< 20) Submitted: 5/5/2007 11:23:19 PM : Underperform Start Price: $54.60 CYCC Score: +144.86

This is one of Zack's #1 rated stocks. I do not understand their reasoning for this though. The chart that came up on my computer showed this stock starting at around zero and then going on a very steady decline to at least minus 100%. Call me crazy, but I can't see much of a future in this stock unless it is bought by one of the bigger companies.

Results 1 - 11 of 11

Featured Broker Partners


Advertisement